Breathing new life into Inhalation Therapy.

BIOTECH WEBSITE & BRAND STRATEGY

Aerami Therapeutics

Rebrand and redefine the Aerami brand identity and educate stakeholders of its technology.

We shaped consumer perception by infusing elements of Aerami technology into the brand identity.

We communicated the inherent value of the Aerami brand by educating consumers with an engaging, innovative video to illustrate how the technology works and the benefits provided.

Deliverables
Brand Strategy
Corporate Identity
Website Design + Development
Corporate Video
Stationery
Brand Guidelines
biotech website
biotech website
biotech brand strategy
Aerami Case Study
Aerami Case Study
biotech website

AERAMI CASE STUDY OVERVIEW: BIOTECH BRANDING DELIVERABLES

STRATEGY

Establishing the foundation for the overall visual design.

With the renaming of the brand to Aerami Therapeutics, the company sought to educate consumers about its proprietary inhalation technology to treat severe respiratory diseases. Our brand strategy set to build the identity by implementing the actual technology into the logo itself incorporating air into the brand.

Tone, feel, typography and color palette are airy and light. The Aerami website was designed to speak to multiple audiences and be the center of all marketing and press activity.

We also sought to leverage the power of short-form content by way of video to engage and educate consumers about the smart inhaler. We concepted, storyboarded, scripted, cast, shot and edited video in less than 3 weeks to launch to deadline. The video was integrated into the Aerami website. On-point collateral materials were developed to support.

 

ABOUT AERAMI THERAPEUTICS

Overview of Company.

Aerami Therapeutics is committed to developing improved therapies for the treatment of severe respiratory diseases. Their product development approach combines novel formulations of existing drugs with our inhalation technology for the treatment of severe respiratory diseases with high unmet need. Their lead asset is inhaled imatinib (AER-901) for the treatment of pulmonary arterial hypertension.